Drug Profile
Oncomer
Alternative Names: OncomerLatest Information Update: 03 Aug 2007
Price :
$50
*
At a glance
- Originator Coremed
- Class Antineoplastics; Coagulants
- Mechanism of Action Thrombin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 15 Sep 2004 Preclinical trials in Solid tumours in USA (Injection)